EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort

Katja S Gümüs, Anna Teegelbekkers, Max Sauter, Andreas D Meid, Jürgen Burhenne, Johanna Weiss, Antje Blank, Walter E Haefeli, David Czock

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1364 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Katja S Gümüs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Hypericum, Tacrolimus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus is metabolized by cytochrome P450 3A (CYP3A) and is susceptible to interactions with the CYP3A and P‐glycoprotein inducer St. John's Wort (SJW). CYP3A isozymes are predominantly expressed in the small intestine and liver. Prolonged‐release tacrolimus (PR‐Tac) is largely absorbed in distal intestinal segments and is less susceptible to CYP3A inhibition. The effect of induction by SJW is unknown. In this randomized, crossover trial, 18 healthy volunteers received single oral tacrolimus doses (immediate‐release [IR]‐Tac or PR‐Tac, 5 mg each) alone and during induction by SJW. Concentrations were quantified using ultra‐high performance liquid chromatography coupled with tandem mass spectrometry and non‐compartmental pharmacokinetics were evaluated. SJW decreased IR‐Tac exposure (area under the concentration‐time curve) to 73% (95% confidence interval 60%‐88%) and maximum concentration (C max ) to 61% (52%‐73%), and PR‐Tac exposure to 67% (55%‐81%) and C max to 69% (58%‐82%), with no statistical difference between the 2 formulations. The extent of interaction appeared to be less pronounced in volunteers with higher baseline CYP3A4 activity and in CYP3A5 expressors. In contrast to CYP3A inhibition, CYP3A induction by SJW showed a similar extent of interaction with both tacrolimus formulations. A higher metabolic baseline capacity appeared to attenuate the extent of induction by SJW.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypericumTacrolimusHumansCytochrome P-450 CYP3ADrug InteractionsPlant ExtractsCross-Over Studies

Stichwörter der Autor:innen

St. John's Wortdrug formulationdrug-drug interactionpharmacogeneticstacrolimus

Substanzen

Cytochrome P-450 CYP3APlant ExtractsTacrolimus

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.

Zitieren

APA

Gümüs, K. S., Teegelbekkers, A., Sauter, M., Meid, A. D., Burhenne, J., Weiss, J., Blank, A., Haefeli, W. E., & Czock, D. (2024). Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1364

Vancouver

Gümüs KS, Teegelbekkers A, Sauter M, Meid AD, Burhenne J, Weiss J, et al. Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1364

BibTeX
@article{Gms2024,
  author = {Gümüs, Katja S and Teegelbekkers, Anna and Sauter, Max and Meid, Andreas D and Burhenne, Jürgen and Weiss, Johanna and Blank, Antje and Haefeli, Walter E and Czock, David},
  title = {Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1364}
}
Kostenlos starten →